Drug-drug interactions of new active substances: Mibefradil example

European Journal of Clinical Pharmacology

Volumn 55, Issue 8, 1999, Pages 559-565

  Krayenbuhl J C ^a   Vozeh, S ^a   Kondo Oestreicher, M ^b   Dayer, P ^b  

^a Swiss Intercant Off Contr of Med   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Interaction studies; Mibefradil interactions; Withdrawal

Indexed keywords

ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; CYCLOSPORIN; CYTOCHROME P450; DEXTROMETHORPHAN; DIGOXIN; DILTIAZEM; FLECAINIDE; METOPROLOL; MEVINOLIN; MIBEFRADIL; NICARDIPINE; PROPAFENONE; QUINIDINE; SIMVASTATIN; TACROLIMUS; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ANGINA PECTORIS; AREA UNDER THE CURVE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; MORTALITY; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; QT INTERVAL; REVIEW; TORSADE DES POINTES;

CALCIUM CHANNEL BLOCKERS; DRUG APPROVAL; DRUG INTERACTIONS; HUMANS; MIBEFRADIL; PRODUCT SURVEILLANCE, POSTMARKETING; SWITZERLAND;

EID: 0032865362     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050673     Document Type: Review

References (37)

1. Po ALW, Zhang W Y (1998) What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 351: 1829-1830
2. Kleinke JD, Gottlieb S (1998) Is the FDA approving drugs too fast? BMJ 317: 899
3. Weerasuriya K (1998) Mibefradil: the sole exception. Lancet 352: 823-824
4. Mulder P, Richard V, Compagnon P, Henry JP, Lallemand F, Clozel JP, Koen R, Macé B, Thuillez C (1997) Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. JACC 29:416-421
5. Billman GE (1992) Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation. Eur J Pharmacol 229: 179-187
6. Brogden RN, Markham M (1997) Mibefradil. A review. Drugs 54: 774-793
7. Welker HA, Wiltshire H, Bullingham R (1998) Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet 35: 405-423
8. Wiltshire HR, Sutton BM, Heeps G, Betty AM, Angus DW, Harris SR, Worth E, Welker HA (1997) Metabolism of the calcium antagonist, mibefradil, (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man. Xenobiotica 27: 557-571
9. Anonymous (1998) Arzneimittelkompendium der Schweiz. Swiss Product Information. Posicor, Documed
10. Spoendlin M, Peters J, Welker H, Bock A, Thiel G (1998) Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Nephrol Dial Transplant 13: 1787-1791
11. Anonymous (1998) Arzneimittelkompendium der Schweiz. Swiss Product Information. Isoptin RR, Documed
12. Palmer B, Dawidson I, Sagalowsky A, Sandor Z, Lu C (1991) Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 52: 640-645
13. Meredith PA (1997) Clinical relevance of optimal pharmacokinetics in the treatment of hypertension. J Hypertens 15[suppl 5]: S27-S31
14. Massie BM, Lacourcière Y, Viskoper R, Woittiez A, Kobrin I (1997) Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists. Am J Cardiol 80: 27C-33C
15. Alpert JS, Bakx LM, Braun S, Frishman WH, Schneeweiss A, Tzivoni D, Kobrin I (1997) Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris. Am J Cardiol 80: 20C-26C
16. Davies GJ, Tzivoni D, Kobrin I (1997) Mibefradil in the treatment of chronic stable angina pectoris: comparative studies with other calcium antagonists. Am J Cardiol 80:34C-39C
17. Braun S, van der Wall EE, Emanuelsson H, Kobrin I (1996) Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol 27: 311-316
18. Anonymous (1998) Physician's desk reference, 52nd edn. Posicor Medical Economics Company
19. SCRIP (1997) FDA panel recommends Roche's Posicor. PJB Publications no. 2212, 7 March, p 20
20. Roden DM (1997) Cardiovascular and renal advisory panel of the US food and drug administration considers four drugs. Circulation 95: 2335-2337
21. Menafoglio A, Krähenbühl S, Canonica C, Togni PL, Zwahlen H, Marone C, Gallino A (1998) Interaction entre tacrolimus et mibéfradil Schweiz (abstract). Med Wochenschr 128[suppl 96]: 113
22. Wagner J, Ritz E (1998) Induktion von Bradykardie durch Mibefradil bei antihypertensiver Kombinationstherapie. Deutsche Med Wochenschr 123: 547
23. Anonymous (1997) (975/RP) Posicor Tabletten 50 mg und 100 mg; IKS-Nr. 53,937 Risikomindernde Massnahmen/Sicherheitsrelevante Änderungen der Arzneimittel-information. Roche Pharma (Schweiz) AG
24. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schnutz J, Haefeli WE (1998) Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 351: 1929
25. Anonymous (1998) L'utilisation appropriée du Posicor chez les transplantés. Roche Pharma (Schweiz) AG
26. Communiqué de Presse (1998) 8 Juin Basel, Roche annonce le retrait volontaire du Posicor
27. Anonymous (1998) Basel, 5. Juni 1998 Wichtige Mitteilung. Freiwilliger weltweiter Rückzug von Posicor. Roche Pharma AG
28. Anonymous (1998) Basel, 12. Juni 1998. Rückzug von Posicor: Information zur Umstellung. Roche Pharma AG
29. SCRIP (1998) Life-threatening reactions after Posicor switching. PJB Publications Ltd. no. 2346, 24 June, p 19
30. Mullins ME, Horowitz Z, Linden DHJ, Smith GW, Norton RL. Stump J (1998) Life-threatening interaction of mibefradil and β-blockers with dihydropyridine calcium channel blockers. JAMA 280: 157-158
31. SCRIP (1998) Posicor ups mortality in heart failure. PJB Publications no. 2368, 9 September, p 29
32. Gascon MP, Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41: 573-578
33. Ha HR, Candinas R, Stieger B, Meyer UA, Follath F (1996) Interaction between amiodarone and lidocaine. J Cardiovasc Pharmacol 28: 533-539
34. Fabre GF, Julian B, Saint-Aubert B, Joyeux H, Berger Y (1993) Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 21: 978-985
35. Department of Health and Human Services FDA (1997) Drug metabolism/drug interaction studies in the drug development process: studies in vitro. Guidance for Industry
36. Committee for proprietary medicinal products (1997) Note for guidance on the investigation of drug interactions. The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit
37. Vozeh S, Steimer JL, Rowland M, Morselli P, Mentré F, Balant LP, Aarons L (1996) The use of population pharmacokinetics in drug development. Clin Pharmacokinet 30: 81-93